Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children.

Autor: Hieda O; Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Kyoto, 602-8566, Japan. ohieda@koto.kpu-m.ac.jp., Hiraoka T; Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan., Fujikado T; Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan., Ishiko S; Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan., Hasebe S; Department of Ophthalmology 2, Kawasaki Medical School, Kurashiki, Okayama, Japan., Torii H; Department of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan., Takahashi H; Department of Ophthalmology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan., Tanaka S; Clinical Biostatistics Course, School of Public Health, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan., Kinoshita S; Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Jazyk: angličtina
Zdroj: Japanese journal of ophthalmology [Jpn J Ophthalmol] 2023 Sep; Vol. 67 (5), pp. 602-611. Date of Electronic Publication: 2023 Aug 07.
DOI: 10.1007/s10384-023-01012-8
Abstrakt: Purpose: Having previously demonstrated the efficacy of 0.01% atropine eye drops for inhibiting progression of childhood myopia, we conducted additional analyses to assess post-treatment changes in myopia progression.
Study Design: Analysis of follow-up data from a previously reported randomized controlled trial METHODS: A mixed-effects model was used to compare intergroup changes in spherical equivalent (SE) and axial length (AL) at 1 month and 12 months after discontinuation of 2-year treatment with atropine or placebo in 167 school-age children.
Results: Follow-up measurements were available for 149 participants at 1 month after discontinuation of treatment and for 51 participants at 12 months after discontinuation. At 1 month post-treatment, differences between the atropine and placebo groups in least squares (LS) mean changes in SE and AL, respectively, from 24 months were -0.06 diopters (D) (95% CI: -0.21, 0.08; P = .39) and 0.02 mm (95% CI: -0.05, 0.08; P = .60). At 12 months post-treatment, intergroup differences (atropine vs placebo) in LS mean changes in SE and AL, respectively, were -0.13 D (95% CI: -0.35, 0.10; P = .26) and -0.02 mm (95% CI: -0.12, 0.09; P = .75). LS mean changes in SE and AL from treatment discontinuation did not differ between the groups at 1 or 12 months post-treatment.
Conclusion: Axial elongation was significantly less in the atropine group than in the placebo group. The suppression effect obtained at 2 years was maintained after 12 months. The absence of intergroup differences in myopia progression since treatment cessation suggests that myopic rebound did not occur.
(© 2023. Japanese Ophthalmological Society.)
Databáze: MEDLINE
Externí odkaz: